Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cardiff Oncology, Inc. (CRDF)
NASDAQ:CRDF
Holding CRDF?
Track your performance easily
CRDF Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.94 - $6.42
Previous Close$2.46
Volume382.73K
Average Volume (3M)549.77K
Market Cap
$114.51M
Enterprise Value$56.04M
Total Cash (Recent Filing)$60.32M
Total Debt (Recent Filing)$1.84M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Oct 31, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.91
Shares Outstanding46,549,634
10 Day Avg. Volume450,104
30 Day Avg. Volume549,771
Standard Deviation0.41
R-Squared0.06
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)2.24
Price to Sales (P/S)177.80
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue84.26
Enterprise Value/Gross Profit114.83
Enterprise Value/Ebitda-1.32
Forecast
1Y Price Target
$8.00Price Target Upside225.20% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Cardiff Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe totality of the data generated by onvansertib + chemo/bev is viewed as promising.
Financial HealthCardiff's financial resources are believed to be sufficient to provide an operational runway into 3Q25.
Regulatory MilestonesCRDF-005 trial may position onvansertib for accelerated approval based on an ORR interim analysis.
Bears Say
Clinical Trial ProgressInitial CRDF-004 trial readout now expected later due to a lower than anticipated pace of enrollment.
Clinical Trial ResultsThe randomized ONSEMBLE trial in 2L RAS+ CRC was halted, indicating a shift in company strategy.
Financial HealthCRDF reported a net loss, which may raise concerns about the company's financial sustainability.
---
Ownership Overview
26.27% Insiders
5.18% Mutual Funds
13.59% Other Institutional Investors
54.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRDF FAQ
What was Cardiff Oncology, Inc.’s price range in the past 12 months?
Cardiff Oncology, Inc. lowest stock price was $0.94 and its highest was $6.42 in the past 12 months.
What is Cardiff Oncology, Inc.’s market cap?
Currently, no data Available
When is Cardiff Oncology, Inc.’s upcoming earnings report date?
Cardiff Oncology, Inc.’s upcoming earnings report date is Oct 31, 2024 which is in 42 days.
How were Cardiff Oncology, Inc.’s earnings last quarter?
Cardiff Oncology, Inc. released its earnings results on Aug 08, 2024. The company reported -$0.26 earnings per share for the quarter, missing the consensus estimate of -$0.248 by -$0.012.
Is Cardiff Oncology, Inc. overvalued?
According to Wall Street analysts Cardiff Oncology, Inc.’s price is currently Undervalued.
Does Cardiff Oncology, Inc. pay dividends?
Cardiff Oncology, Inc. does not currently pay dividends.
What is Cardiff Oncology, Inc.’s EPS estimate?
Cardiff Oncology, Inc.’s EPS estimate is -$0.27.
How many shares outstanding does Cardiff Oncology, Inc. have?
Cardiff Oncology, Inc. has 46,549,633 shares outstanding.
What happened to Cardiff Oncology, Inc.’s price movement after its last earnings report?
Cardiff Oncology, Inc. reported an EPS of -$0.26 in its last earnings report, missing expectations of -$0.248. Following the earnings report the stock price went up 11.737%.
Which hedge fund is a major shareholder of Cardiff Oncology, Inc.?
Among the largest hedge funds holding Cardiff Oncology, Inc.’s share is Graham Capital Management, L.P.. It holds Cardiff Oncology, Inc.’s shares valued at 93K.
---
Cardiff Oncology Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (225.20% Upside)
$8.00 (225.20% Upside)
Blogger Sentiment
Bullish
CRDF Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 81.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 3.1%
Last 30 Days ▼ 3.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
45.56%
12-Months-Change
Fundamentals
Return on Equity
-58.80%
Trailing 12-Months
Asset Growth
-32.22%
Trailing 12-Months
Company Description
Cardiff Oncology, Inc.
Trovagene, Inc. is a clinical-stage, precision cancer medicine oncology therapeutics company, which engages in the development of drugs that target cell division (mitosis), for the treatment of various cancers including leukemia, lymphomas, and solid tumors. The company was founded by Gabriel M. Cerrone, L. David Tomei, Samuil Umansky, and Hovsep Melkonyan on August 4, 1999 and is headquartered in San Diego, CA.
---
CRDF Earnings Call
Q2 2024
0:00 / 0:00
---
CRDF Stock 12 Month Forecast
Average Price Target
$8.00
▲(225.20% Upside)
Technical Analysis
ADC Therapeutics
―
Atara Biotherapeutics
―
Gritstone Oncology
―
Oncternal Therapeutics
―
Best Analysts Covering CRDF
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
+0.75%
reiterated a buy rating 12 months ago
Copying Joel Beatty's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of +0.75% per trade.
---